Compare BioNano Genomics Inc (BNGO) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Trade Desk Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Trade Desk Inc trades at $13.46 (market cap $6.37B). The key difference: Trade Desk Inc is far larger — about 466.3× BioNano Genomics Inc's market cap. Which is the better fit depends on your goals.
| BNGO | TTD | |
|---|---|---|
Market Cap | $13.66M | $6.37B |
Sector | Health | Technology |
52-Week High | $4.92 | $55.36 |
52-Week Low | $1.06 | $13.39 |
Enterprise Value | $16.26M | $5.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
The Trade Desk (TTD) trades at $13.66, down 90% from its 2024 peak, with bearish technical signals and recent earnings misses. Revenue growth slowed to 3% in Q2 2026, and Q3 guidance projects a 12% decline. Despite strong profitability margins (net margin 13.6%), the stock faces execution challenges and advertiser pressure. Analyst sentiment is mixed with a $13.87 price target, while institutional selling and downgrades reflect mounting concerns.
Outlook remains cautious amid weak guidance and competitive threats, though current valuations (P/E 16.1) may attract value investors. Key risks include persistent revenue declines and market share erosion. Recovery hinges on stabilizing advertiser relationships and reversing recent execution gaps.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
